Sino Biopharmaceutical Limited
GPTKB entity
Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:awards |
gptkb:Forbes_Asia's_Fab_50_Companies
China Top 100 Pharmaceutical Industry Enterprises |
| gptkbp:businessModel |
manufacturing of pharmaceuticals
research and development of pharmaceuticals sales of pharmaceuticals |
| gptkbp:CEO |
Tse Ping
|
| gptkbp:chairman |
Tse Ping
|
| gptkbp:founded |
2000
|
| gptkbp:founder |
Tse Ping
|
| gptkbp:hasResearchCenter |
gptkb:Beijing
gptkb:Hong_Kong gptkb:Nanjing gptkb:Shanghai gptkb:United_States |
| gptkbp:headquarters_location |
gptkb:Beijing,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sino Biopharmaceutical Limited
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
KYG8167W1380
|
| gptkbp:listedOn |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:marketCap |
over US$10 billion (as of 2023)
|
| gptkbp:notableProduct |
antibiotics
generic drugs diabetes drugs analgesic drugs biological drugs innovative drugs Chinese medicine preparations anti-tumor drugs cardiovascular system drugs chemical drugs liver disease drugs modern traditional Chinese medicine respiratory system drugs |
| gptkbp:numberOfEmployees |
over 20,000
|
| gptkbp:parentCompany |
gptkb:Chia_Tai_Group
|
| gptkbp:products |
pharmaceuticals
biotechnology products oncology drugs cardiovascular drugs hepatitis drugs |
| gptkbp:R&D_investment |
over RMB 2 billion annually
|
| gptkbp:servesArea |
gptkb:Asia
gptkb:China |
| gptkbp:stockSymbol |
1177.HK
|
| gptkbp:subsidiary |
CT Tianqing Pharmaceutical Group
Chia Tai – Tianqing Pharmaceutical Group |
| gptkbp:website |
http://www.sinobiopharm.com/
|
| gptkbp:主要株主 |
Tse Ping family
|
| gptkbp:bfsParent |
gptkb:GeneMedix
|
| gptkbp:bfsLayer |
7
|